The near-term outlook for ClearPoint's biopharma business is also now clouded by FDA uncertainty around uniQure's AMT-130.

Acquisition Will Further Expand the Potential of ClearPoint Neuro's Drug Delivery Portfolio While Immediately Adding New Indications and Commercial Scale Across a $0.5 Billion Market for the Treatment ...

ClearPoint Neuro ( (CLPT)) just unveiled an announcement. On November 6, 2025, ClearPoint Neuro reported its third-quarter financial results, highlighting a 9% year-over-year revenue increase to $8.9 ...

SOLANA BEACH, California - ClearPoint Neuro, Inc. (NASDAQ:CLPT) announced Thursday it will acquire IRRAS Holdings, Inc., a San Diego-based medical technology company specializing in neurocritical care ...

Members of the ClearPoint Neuro management team will be onsite and available for in-person investor meetings who are registered to attend the various conferences. Statements in this press release and ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.18 per share a year ago. These ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. Clearpoint Credit Counseling Solutions was a nonprofit organization that specialized in ...

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as ...

ClearPoint Neuro (CLPT) stock soared on Friday alongside new filings with the Securities and Exchange Commission (SEC). In these filings, the company revealed new insider buying from three members of ...

We are actively working to enhance your experience by translating more content. However, please be aware that the page you are about to visit has not yet been translated. We appreciate your ...